Comparative Pharmacology
Head-to-head clinical analysis: BUPRENORPHINE HYDROCHLORIDE versus PIVYA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPRENORPHINE HYDROCHLORIDE versus PIVYA.
BUPRENORPHINE HYDROCHLORIDE vs PIVYA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors, producing analgesia and reducing opioid withdrawal symptoms.
Pivya (pivmecillinam) is a prodrug of mecillinam, a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding protein 2 (PBP2), leading to defective cell wall formation and cell death.
Sublingual: 8-16 mg once daily. Transdermal: 5-20 mcg/hour applied every 7 days. Injectable: 0.3 mg IM/IV every 6-8 hours as needed.
1200 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 20-73 hours (mean ~37 hours); prolonged half-life supports sublingual dosing every 24-48 hours in opioid dependence.
Terminal elimination half-life of 3-4 hours in patients with normal renal function; may be prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Primarily fecal (70%) via biliary excretion; renal excretion accounts for 20-30% as unchanged drug and metabolites (mainly norbuprenorphine glucuronide).
Primarily renal excretion as unchanged drug (approximately 70-80%); biliary/fecal excretion accounts for 10-15%.
Category C
Category C
Opioid Partial Agonist
Opioid Partial Agonist